LUNG AND MEDIASTINUM: Edited by Robert PirkerEpidemiology and risk factors for venous thromboembolism in lung cancerAy, Cihan; Ünal, Umut KaanAuthor Information aDepartment of Medicine I, Clinical Division of Haematology and Haemostaseology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria bIstanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey Correspondence to Cihan Ay, MD, Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel: +43 1 40400 44100; fax: +43 1 40400 40300; e-mail: [email protected] Current Opinion in Oncology: March 2016 - Volume 28 - Issue 2 - p 145-149 doi: 10.1097/CCO.0000000000000262 Buy Metrics Abstract Purpose of review Cancer is a strong risk factor for venous thromboembolism (VTE). In patients with lung cancer VTE is a significant cause for morbidity and mortality. The purpose of the review is to summarize the epidemiology of thrombotic events, risk factors for VTE and the clinical impact of VTE in patients with lung cancer. Recent findings The rates of VTE in lung cancer patients vary according to different types of investigations, and reach 7 to 13%, including a significant number of unsuspected pulmonary emboli. Risk factors for VTE in patients with lung cancer can be basically divided into three categories: patient, tumor, and treatment related. In addition, a number of biomarkers have been described to be associated with VTE risk (e.g., D-dimer). Summary Knowledge about the epidemiology, risk factors, and prognostic value of VTE in lung cancer could help to prevent thrombotic complications and improve management of patients with lung cancer. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.